Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine

Leukemia Research
Thorsten GraefGuido Kobbe

Abstract

Therapeutic options for patients with relapse of MDS or high risk AML after allogeneic stem cell transplantation are limited. We here present the case of a 64-year-old female patient with MDS, who received peripheral blood stem cells from her HLA-identical brother after a non-myeloablative conditioning regimen. Two months after allogeneic transplantation she suffered from a relapse, now fulfilling WHO criteria for AML with a bone marrow blast count of 91%. We then decided to treat her with azacitidine, a DNA methyltransferase inhibitor with proven antileukemic activity. The patient achieved a complete haematological response after two cycles and full donor chimerism after a single dose of donor lymphocytes. We postulate that azacitidine acts through a direct reduction of malignant cells and may in addition augment the immunologic effects of donor lymphocyte infusions.

References


❮ Previous
Next ❯

Citations

May 1, 2012·Bone Marrow Transplantation·M ChristopeitU Bacher
Sep 2, 2010·Current Opinion in Oncology·Ulrike BacherTorsten Haferlach
Jun 2, 2012·Clinical Medicine Insights. Oncology·Tara L Lin, M Yair Levy
Mar 20, 2014·Current Hematologic Malignancy Reports·Amir T Fathi, Yi-Bin Chen
Aug 22, 2015·Expert Review of Anticancer Therapy·Abdallah Abou ZahrAmer M Zeidan
Feb 1, 2009·Expert Opinion on Drug Discovery·Xavier ThomasJacques Troncy
Jul 18, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Hans C LeeRichard Champlin
Dec 11, 2007·Blood Reviews·Eva Hellström-Lindberg, Luca Malcovati
Sep 4, 2008·American Journal of Hematology·Celalettin UstunAnand Jillella
Apr 8, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ling GeXiaowen Tang
Mar 31, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ibraheem H MotabiJohn F DiPersio
Feb 4, 2014·Journal of Geriatric Oncology·Haifa Kathrin Al-AliDietger Niederwieser
Mar 17, 2015·Bone Marrow Transplantation·J SteinmannM Lübbert
Mar 17, 2018·Expert Review of Hematology·Guido KobbeUlrich Germing
Oct 27, 2009·Bone Marrow Transplantation·B N SavaniK Rezvani
Nov 17, 2017·International Journal of Hematology·Thomas SchroederGuido Kobbe
Nov 17, 2020·Clinical Lymphoma, Myeloma & Leukemia·Georg-Nikolaus FrankeUwe Platzbecker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.